Evotec AG
March 2008

Translating Innovation into Results



Forward-looking statements

Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec´s products, the timing of the completion of the transaction between Evotec and Renovis, the anticipated benefits of the business combination transaction involving Evotec and Renovis, including future financial and operating results, the combined company's plans, objectives, expectations and intentions, the anticipated timing and results of the combined company's clinical and pre-clinical programs, and other statements that are not historical facts. Evotec and Renovis caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties' ability to complete the transaction because conditions to the closing of the transaction may not be satisfied; the failure to successfully integrate the businesses; unexpected costs or liabilities resulting from the transaction; the risk that synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. The risks included above are not exhaustive. The most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Renovis with the Securities and Exchange Commission contain additional factors that could impact the combined company's businesses and financial performance. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information

Renovis filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 24, 2007, that includes as an exhibit the Agreement and Plan of Merger between Evotec and Renovis. Evotec filed a Registration Statement on Form F-4 with the Securities and Exchange Commission in connection with the proposed merger. Evotec and Renovis expect to mail a joint proxy statement/prospectus, which will form part of the Registration Statement on Form F-4, to shareholders of Renovis in connection with the proposed merger. This document will contain important information about the merger and should be read before any decision is made with respect to the merger. Investors and stockholders will be able to obtain free copies of this document and any other documents filed or furnished by Evotec or Renovis through the website maintained by the Securities and Exchange Commission at www.sec.gov. Free copies of these documents may also be obtained from Evotec, by directing a request to Evotec's Investor Relations department at Schnackenburgallee 114, 22525 Hamburg, Germany, or from Renovis, by directing a request to Renovis' Investor Relations department at Two Corporate Drive, South San Francisco, California 94080.

In addition to the documents referenced above, Renovis files or furnishes annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy any reports, statements or other information filed or furnished by Renovis at the SEC's Public Reference Room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. Renovis's SEC filings are also available to the public at the SEC's web site at www.sec.gov, or at their web site at www.renovis.com.

Evotec highlights

- Powerful track record in drug discovery and development
- Attractive CNS pipeline with compounds in blockbuster indications
- €30 - 35m in partnership revenues
- Proposed merger with Renovis to build global CNS pure play, closing Q2 2008
- Frankfurt SE listed, anticipated NASDAQ listing Q1 2008

CNS Pipeline



Strategic transformation



Strategic transformation

Strategic transformation

New Evotec



*Note: Based on end of September 2007 cash plus proceeds from the disposal of Evotec's Chemical Development Business prior to transaction costs.

The combination: Multi-faceted pipeline, strong fit and differentiating science



Lead compound: EVT 201 in insomnia

- Small molecule partial positive allosteric modulator (pPAM) of $GABA_A$ receptors
- Addresses limitations of market-leading insomnia drugs
  - Sleep onset, maintenance, no hangover
  - Same dose for young and elderly
- Proof-of-concept established
  - Strong Phase II POC data from study 2005, 149 elderly insomniacs
  - Strong Phase II POC data from study 2004, in 67 primary adult insomniacs
  - Strong Phase I and I/II safety and tolerability data from a total of 153 subjects
- Partner-ready, best-in-class opportunity

Revenues 2006	Ambien/Ambien CR	US$ 2.9bn

Study EVT 2004: Robust Phase II results

Highly statistically and clinically meaningful effects on all key endpoints, indicating strong effects on both sleep onset and sleep maintenance with no subjective hangover.

Parameter (N=67)	**Placebo**	**EVT 201** (1.5 mg)	**EVT 201** (2.5 mg)	**p value both doses**
Adjusted mean WASO (mins)*	64	47 (26%)	38 (40%)	p<0.0001
Adjusted mean TST (mins)*	379	412 (9%)	424 (12%)	p<0.0001
Adjusted mean LPS (mins)	42	25 (40%)	22 (49%)	p<0.0001
Adjusted mean Total Wake Time 2nd half (mins)	43	32 (25%)	27 (38%)	p<0.0001 (2.5mg) p=0.0008 (1.5mg)
Adjusted mean SWS (mins)	30	30 (2.4%)	30 (0.7%)	NS
Subjective sleep quality (very good/good)	41%	75%	79%	p<0.0001
Adjusted mean DSST (number correct)	58.5	56.2	54.3	p<0.0001 (2.5mg) p=0.0028 (1.5mg)
Subjective residual sedation (very alert/somewhat alert in %)	53%	58%	48%	NS

*** Co-primary endpoint**

Randomized cross-over study in 67 patients; 1.5 mg & 2.5 mg doses vs. placebo for 2 consecutive nights with a 5-12 day washout between each period

Study EVT 2004: Objective efficacy from polysomnography
Total Wake Time hour-by-hour



EVT 201 significantly reduced Total Wake Time each hour except of hour 7
(where p=0.058)

Study EVT 2004: Subjective residual effects
Patient reported residual sedation



No subjective residual sedation at either dose of EVT 201

Study EVT 2004: Subjective efficacy
Patient reported sleep quality



Both doses markedly & signifi-cantly improved categorical ratings of sleep quality

Study EVT 2005: Daytime sleepiness
Multiple Sleep Latency Test (MSLT)

Multiple Sleep Latency Test (MSLT)



Both doses of EVT 201 significantly increased MSLT

Error bars represent 95% confidence interval

Study EVT 2005:
Summary of Phase II in elderly primary insomniacs

- Results in elderly confirm results in young
- Same doses in elderly insomniacs and normal adults lead to robust effects on both sleep onset and sleep maintenance
- No significant residual effects
- Patients significantly less sleepy the day after 1 week treatment determined Multiple Sleep Latency Test (MSLT)
- EVT 201 safe, well tolerated
- Further analysis is ongoing

Study EVT 2004: Comparative efficacy % and actual change from placebo

	EVT 201 1.5 mg	EVT 201 2.5 mg	Almorexant 100 mg	Almorexant 200 mg	Lunesta 3 mg	Ambien 10 mg	Indiplon MR 30 mg	Gaboxadol 20 mg	Ambien 10 mg
WASO	26% (16.7 mins)	40% (25.7 mins)	29% (20 mins)	39% (34 mins)	17% (7.2 mins) p=0.012	9% (3.8 mins) ns	21% (21.3 mins)	24% (8 mins) p<0.01	4% (1.4 mins) ns
LPS	40% (17.1 mins)	49% (21 mins)	22% (10.4 mins)	27% (10.4 mins)	52% (19.5 mins)	56% (21 mins)	58% (15 mins)	No effect	SOL: 30% (6.5 mins)

WASO = Wake After Sleep Onset; LPS = Latency to Persistent Sleep

- **EVT 201 – comparable or much stronger effect on WASO**
- **EVT 201 – comparable or stronger effect on LPS**

vs. Almorexant, Lunesta, Zolpidem and Indiplon MR (elderly)

EVT 201 summary from all clinical studies: Potential advantages for chronic insomniacs

Robust efficacy	• Sleep onset, maintenance, no hangover
Improved sleep quality	• Without residual sedation
Next day benefits	• Significantly reduced daytime sleepiness
Novel, but “Gold Standard” insomnia MOA	• Highly validated pathway • Lower side effect risk
One drug to address market needs	• Optimal PK for all patients • No need for sustained release • Corresponding dose range for adults and elderly
Differentiation vs. other GABA-based treatments: partial modulation	• High affinity, α1 preferring partial positive allosteric modulator • Lower maximum level of $GABA_A$ receptor system potentiation • Reduced side-effect potential (e.g. dependence, tolerance, alcohol interaction, disturbance of sleep architecture)

EVT 101:
Oral NR2B subtype selective NMDA receptor antagonist

- Subtype selectivity of EVT 101 NMDA supports hypothesis of better side effect profile, better efficacy in Alzheimer's
- Memantine / Namenda, a non-selective NMDA drug in Alzheimer's disease, reached blockbuster sales in year 3
- Potential in neurodegenerative diseases, peri-operative and neuropathic pain
- Status
  - Phase I successfully completed
  - Phase Ib studies ongoing
  - Phase II POC study planned to start mid 2008



NR1



$NR2_A$



[3H]Ro 25-6981



$NR2_B$



$NR2_C$

Revenues 2006	Namenda/Ebixa	US$ 0.9bn

EVT 101 ongoing trials and plans

- Phase Ib cognition and brain imaging study
  - Randomized, double-blind, single dose (8mg, 15mg) in 19 healthy volunteers
  - Determine changes in neuronal activity, CNS penetration, dose response
  - Read-out: Q1 2008
- Phase Ib repeat dose cognition study
  - Randomized, double-blind, ascending dose, 4 wk, 48 young / elderly subjects
  - Determine effects of longer term treatment on cognition, safety and tolerability
  - Read-out: Q2 2008
- Phase II POC planned

EVT 302:
Selective MAO-B inhibitor smoking cessation and Alzheimer's

- Orally active, potent, highly selective MAO-B inhibitor
  - Potential for once weekly dosing
  - Competitive safety & tolerability profile over other MAO-B inhibitors – no food effect / label
- Validating MOA data in addiction & neurodegeneration
  - Phase II in smoking cessation (selegiline, lazabemide)
  - Phase III in Alzheimer's Disease
- Smoking cessation - a large consumer-driven market
- Status
  - Phase II started
  - Phase I safety study successfully completed
  - Additional Phase I data in H1 2008

Revenues 2007	Chantix	US$ 0.9bn

EVT 302 ongoing trials

- Phase II craving study
  - Influence on craving / withdrawal after short-term deprivation of cigarettes
  - Randomized, double-blind, 3-way cross-over of single doses (nicotine + placebo)
  - Secondary outcome: Effect when combined with Nicotine Replacement Therapy
  - Read-out: Q3 2008
- Phase I Positron Emission Tomography (PET) studies
  - Open-label, single and multiple dose (5 or 15mg), 18 subjects/study
  - Completed, data in Q1 2008
- Tyramine interaction study
  - Double-blind, placebo-controlled, 60 subjects, against Selegiline
  - To demonstrate lack of tyramine interaction
    (cheese and wine effect, cardiovascular liability)
  - Read-out: H1 2008

EVT 302 trial plans

- Second Phase II POC study
  - Effectiveness of EVT 302 in Smoking Cessation (quit rate), results in 2009
- Phase II study of EVT 302 in Alzheimer‘s Disease
  - To be decided in 2008
  - Not budgeted for

VR1 - Vanilloid Receptor 1 antagonist

Potential for safe, best-in-class analgesic, non-addictive, minimal side effects

- Non-selective cation channel
  - Activated by capsaicin & resiniferatoxin
  - Gated endogenously by heat, protons, lipid metabolites & eicosaniods
  - Multimodal channel – detects more than chemical & thermal noxious stimuli
- Widespread PNS & CNS distribution
- Preclinical & clinical validation
  - Gene disruption and small molecule agonist & antagonist studies
- Potential in various diseases
  - Up-regulated in chronic neuropathic pain
  - Urinary incontinence, IBD, Asthma, etc.
- Status
  - Pfizer partnership: Multiple clinical candidates
  - Planned Phase I start: 06/2008



Revenues 2007	Celebrex	US$ 2.3bn

$P2X_7$ receptor antagonist
Potential best-in-class molecule

- Non-selective ATP-gated ion channel
- Restricted cellular distribution
  - Cells of immune & hematopoietic lineage: macrophages, mast cells, monocytes & lymphocytes
- Involved in multiple signaling pathways: broad anti-inflammatory potential
  - Mediates release of pro-inflammatory cytokines IL-1β & IL-18, MMP-9 release, caspase-1 activation, pore formation & necrotic cell death
- Preclinical & clinical validation
- Multiple large potential indications
  - Pain, RA, IBD, MS, COPD, diabetes
- Status
  - Clinical candidate identified, back-up series
  - Planned Phase I in 2008



Total market 2006	Rheumatoid Arthritis	US$ 12bn

$P2X_{2/3}$ receptor antagonist

- First-in-class and best-in-class $P2X_{2/3}$ receptor antagonist
  - Very good drugability
- Potential in pain and overactive bladder
- Preclinical validation by Roche
- Status
  - Industry has struggled to find drug-like molecules
  - Lead series with superior properties
  - Potential clinical candidate within next 12 months, Phase I to start in H1 2009

Total market 2006	Neuropathic pain	US$ 3.0bn



Validated research track record, ongoing revenue source

High-value partnerships: Milestones expected in 2008, 2009

Post-merger partnership profile

Boehringer Ingelheim	76 FTEs, 5 yr collaboration, milestones, royalties
Pfizer	VR1, US$ 10m in upfront payment, >US$ 10m in FTE funding, >US$ 170m milestones, double-digit royalties
Roche	CNS target, milestones > US$ 140 m, mid-single digit royalties

Key facts on Renovis acquisition

Data un-audited, pro-forma

- NASDAQ listing condition to closing, planned for 03 2008
- Closing subject to shareholder vote 04/05 2008
- R&D budget under review
  - Project prioritization will determine combined budget
- Cash as of September 2007: US$ 231m*
- Expected headcount at closing: approx. 420
- Number of shares outstanding: 108.27m
- Market capitalization as of year end 2007: > US$ 350 m

Note: Based on end of September 2007 cash plus proceeds from the disposal of Evotec's Chemical Development Business, prior to transaction costs. All exchanges are based on currency exchange rates of period end September 2007.

Combined newsflow 2007 - 2008

H2 2007

- Data: EVT 201 Phase II elderly insomniacs ✓
- EVT 101: Initiate Phase Ib fMRI study ✓
  Initiate Phase Ib higher repeat dose study ✓
- Data: EVT 101 Phase Ib fMRI cognition study (Q407/Q108)
- Data: EVT 302 Phase I safety ✓

2008

- NASDAQ listing and merger close
- Partnership: EVT 201 insomnia
- EVT 302: Initiate Phase II in smoking cessation ✓
  Additional Phase I data
- EVT 101: Initiate Phase II POC
- VR1: Initiate Phase I
- P2X7: Initiate Phase I
- EVT 103: Initiate Phase I
- Data: EVT 101 Phase Ib (cogn. full data)

Our “1/2/3/4 in 08” plan Subject to contingencies



Evotec Renovis

Evotec & Renovis
A compelling CNS investment

- Global CNS pure play
- Differentiated lead insomnia compound EVT 201
  - Partner-ready, best-in-class
- Broad and deep pipeline, with clinical momentum
  - Proprietary and partnered
- Fully integrated discovery-through-development core competencies
- Multiple partners generating collaborative revenues: Roche, BI, Pfizer
- Strong pro-forma cash position of US$ 231 m*; Nasdaq liquidity

Note: Based on end of September 2007 cash plus proceeds from the disposal of Evotec's Chemical Development Business, prior to transaction costs. All exchanges are based on currency exchange rates of period end September 2007.

Tomorrow's Drugs Today™



Your contacts:

Jörn Aldag
President & CEO
P: +49.(0)40.56081-375
joern.aldag@evotec.com

Anne Hennecke
SVP, Investor Relations
P: +49.(0)40.56081-286
anne.hennecke@evotec.com